The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor subtype), and they thereby inhibit involuntary bladder contractions. [19] The effective ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The crown jewel of the acquisition was seen as emraclidine, an allosteric modulator that selectively targets the muscarinic acetylcholine 4 receptor subtype. It was seen as a potential next ...

It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...